Aeovian Pharmaceuticals

Executive Summary

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering selective mTORC1 inhibitors for rare genetic and age-related diseases. Its lead candidate, AV078, is a first-in-class, CNS-penetrant small molecule designed to treat tuberous sclerosis complex (TSC) refractory epilepsy by restoring cellular metabolic quality control. The company's platform targets dysregulated growth signaling, with potential applications beyond TSC, including other mTORopathies and neurodegenerative conditions. Currently in Phase 1 clinical development, AV078 has demonstrated favorable safety and pharmacokinetics in initial cohorts, with dose escalation ongoing. Aeovian's approach leverages deep understanding of mTORC1 biology to achieve selectivity over mTORC2, minimizing immunosuppressive and metabolic side effects. Backed by top-tier investors, the company is positioned to address significant unmet needs in TSC, where up to 60% of patients develop refractory epilepsy. The Phase 1 trial's primary objectives are safety, tolerability, and identification of the recommended Phase 2 dose. Preliminary efficacy signals, including seizure reduction in early cohorts, could de-risk the program and support accelerated development. Additionally, the company is advancing preclinical programs for focal cortical dysplasia and Alzheimer's disease, broadening its pipeline. With a strong scientific foundation and a clear regulatory pathway, Aeovian represents a promising investment in precision neurology. Catalysts over the next 12–18 months include Phase 1 data readout, potential Orphan Drug Designation expansion, and initiation of a Phase 2 trial in TSC epilepsy.

Upcoming Catalysts (preview)

• H2 2026Phase 1 safety and efficacy data for AV078 in TSC refractory epilepsy60% success
• Q2 2026Expansion of Orphan Drug Designation (ODD) or Rare Pediatric Disease Designation (RPDD) for AV07875% success
• Q3 2026Series B or additional financing round to fund Phase 2 preparation80% success